Bli medlem
Bli medlem

Du är här


EQL Pharma: EQL Pharma strengthens its organization with Alexander Brising, New Business Development Director

EQL Pharma has recruited Alexander Brising as head of business
development at EQL Pharma. He joined the company in mid-November
2016. Alexander Brising will lead the work to identify new products
for in-licensing or in-house development and thus strengthen an
already strong pipeline of niche generics.

Alexander Brising has a background from leading assignments in the
pharmaceutical industry. Recently he was part of the management team
at Sandoz Nordic headquarter in Copenhagen, where he had budget
responsibility for retail in Sweden. He has an MBA from the
Gothenburg School of Economics.

"To take on the position as head of Business Development at EQL
Pharma is as a very exciting opportunity. EQLs mission to develop
niche generics is very interesting, and I think my strong background
in business development and in identifying product candidates with
high potential, is a perfect match, "says Alexander Brising.

"EQL Pharma continues to focus on putting new niche generics on the
market. In this effort Alexander Brising will play a key role ", says
Christer Fåhraeus, CEO of EQL Pharma.

For further information, please contact:

Christer Fåhraeus

CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00



EQL Pharma AB (publ) in brief

EQL Pharma is specialized in developing and selling generic drugs, ie
drugs that are medically equivalent to the original medicines. The
company currently markets five niche generics in the Swedish and
Danish markets, in addition to these, there are a significant
pipeline of additional niche generics for launch in 2017 and onwards.
The business is currently focused entirely on prescription drugs in
the Nordic region. EQL Pharma is based in Lund, employs seven (7)
people and is listed on AktieTorget. EQL Pharma conducts extensive
development in cooperation with leading contract manufacturers and
major pharmaceutical companies in countries including India and Chin


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.